Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22344866 | 0.97 | — | — | |
| SCHEMBL19975842 | 0.94 | — | — | |
| SCHEMBL16067440 | 0.92 | PDE4B (0.31) | PDE4D | |
| SCHEMBL14090166 | 0.92 | — | — | |
| SCHEMBL19676702 | 0.91 | — | — | |
| SCHEMBL17476440 | 0.90 | — | — | |
| SCHEMBL18973167 | 0.90 | — | — | |
| SCHEMBL17486692 | 0.90 | — | — | |
| SCHEMBL24199959 | 0.89 | — | — | |
| SCHEMBL12347416 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-08 | — | — | US | disclosed |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-04-10 | — | — | US | disclosed |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-03-11 | — | — | US | disclosed |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-12 | — | — | US | disclosed |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-04-18 | — | — | US | disclosed |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-03-16 | — | — | US | disclosed |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-21 | — | — | US | disclosed |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-15 | — | — | US | disclosed |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-09 | — | — | US | disclosed |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-02 | — | — | US | disclosed |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-04-28 | — | — | US | disclosed |
| EP-3949987-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950061-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20220016257-A1 | ANTI-CDH6 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| EP-3882349-A1 | (ANTI-CDH6 ANTIBODY)-(PYRROLOBENZODIAZEPINE DERIVATIVE) CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2021-09-22 | — | — | EP | disclosed |
| CN-113166764-A | anti-CDH 6 antibody-pyrrolobenzodiazepine derivative conjugates | 第一三共株式会社 | 2021-07-23 | — | — | CN | disclosed |
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-3690038-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606634-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | SIGLEC9, DSG1, VSIG8 | SLC6A2 1358/4885PDE4D 4569/4885 |
| US-20220168440-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DEPRIVATIVE CONJUGATE | CD79B, BTD, PDCD1 | SLC6A2 1929/4885PDE4D 1986/4885 |
| US-20240299573-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SLC6A2 1696/4885PDE4D 3494/4885 |
| US-11628223-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines | GABRA1, GABRA4, GABRA2 | SLC6A2 2238/4885PDE4D 3286/4885 |
| US-20200261594-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SLC6A2 1696/4885PDE4D 3494/4885 |
| US-12350344-B2 | Methods of treating a tumor by administering a claudin-6 (CLDN6) or CLDN9 antibody-pyrrolobenzodiazepine derivative conjugate | EPCAM, PDCD6, JUP | SLC6A2 1428/4885PDE4D 4359/4885 |
| US-20220168438-A1 | COMBINATION OF ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND PARP INHIBITOR | PARP2, PARP3, PARP1 | SLC6A2 4408/4885PDE4D 3073/4885 |
| US-20220125943-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SLC6A2 1696/4885PDE4D 3494/4885 |
| US-12246196-B2 | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-a][1,4]diazepines | CNTN1, BTN3A1, FABP6 | SLC6A2 1804/4885PDE4D 4379/4885 |
| US-20230084707-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SLC6A2 1696/4885PDE4D 3494/4885 |
| US-20220016257-A1 | ANTI-CDH6 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, PDCD6IP, PDCD5 | SLC6A2 1565/4885PDE4D 939/4885 |
| US-20250114647-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING SUBSTITUTED BENZO[e]PYRROLO[1,2-a][1,4]DIAZEPINES | CNTN1, BTN3A1, FABP6 | SLC6A2 1798/4885PDE4D 4387/4885 |
| US-11583590-B2 | Antibody-pyrrolobenzodiazepine derivative conjugate and method of use thereof for treating a tumor | EPCAM, PDCD6, CNTN1 | SLC6A2 1605/4885PDE4D 3759/4885 |
| US-20220177601-A1 | ANTI-HER2 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | ERBB2, BRD2, PA2G4 | SLC6A2 3284/4885PDE4D 3503/4885 |
| US-20220395579-A1 | ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE | PDCD6, EPCAM, CNTN1 | SLC6A2 1696/4885PDE4D 3494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.